Rufinamide: 7 agencies, 2008–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused rufinamide: all 11 decisive outcomes across 7 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 16.9 years separate the first record, 25 Nov 2008 at AWMSG (Wales), from the most recent, 30 Oct 2025 at AOTMIT (Poland).
AWMSG (Wales) changed its position: recommended on 25 Nov 2008, restricted by 25 Jun 2019.
No assessment is on file from PBAC (Australia), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
AWMSG (Wales) was first to assess rufinamide, on 25 Nov 2008; AOTMIT (Poland) did not open a file until 26 Aug 2022 — an unusually long tail of 13.8 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 7 years in total.
Restriction is doing real work here: 3 of 11 decisive outcomes narrowed rufinamide to a subgroup rather than accepting or refusing it outright, at AWMSG (Wales) and SMC (Scotland).
4 of the 7 agencies here assessed rufinamide more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for rufinamide.
The full ledger for rufinamide reads 8 recommended, 3 restricted and 2 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 26 Aug 2022 | Inovelon reimbursement recommendation | recommended | source |
| NYE METODER (Norway) | 19 Jun 2022 | Tilleggsbehandling ved epileptiske anfall forbundet med Lennox-Gastaut syndrom hos pasienter fra 1 år | introduced | source |
| PHARMAC (New Zealand) | 11 Feb 2022 | Developmental and epileptic encephalopathies | PTAC advice: High | source |
| AWMSG (Wales) | 25 Jun 2019 | Adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 1 year to < 4 y… | recommended with restrictions (limited) | source |
| HAS (France) | 5 Sep 2012 | Listing (Transparency Committee) | ASMR V | source |
8 further decisions for rufinamide, across 5 agencies, are not shown here. They include the most recent record on file, 30 Oct 2025 from AOTMIT (Poland); its outcome is in the subscriber dataset. They link to 6 further source documents.
Related molecules
- cannabidiol — same ATC class N03A — Antiepileptics
- levetiracetam — same ATC class N03A — Antiepileptics
- perampanel — same ATC class N03A — Antiepileptics
- lacosamide — same ATC class N03A — Antiepileptics
- brivaracetam — same ATC class N03A — Antiepileptics
- zonisamide — same ATC class N03A — Antiepileptics
Coverage: 13 decisions for rufinamide from 7 agencies, 2008 to 2025. Data to 7 Sep 2026. ATC class N03A — Antiepileptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.